Cohance Lifesciences enters into agreements with Chromo Laboratories India

20 Jun 2025 Evaluate

Cohance Lifesciences has entered into an agreements with Chromo Laboratories India for the sale of the assets pertaining to its standalone Clinical Research and Bio-analytical unit (CR Bio), for a consideration of Rs 16 crore. The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations. The said transaction is expected to be completed in Q2 FY26, subject to satisfaction of customary closing conditions under the said agreements. 

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. 


Cohance Lifesciences Share Price

542.20 -6.90 (-1.26%)
05-Dec-2025 15:54 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1520.55
Zydus Lifesciences 933.10
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×